If you are buying or selling a pharmacy in the UK, one number will dominate your negotiations: the goodwill price. Unlike most businesses where goodwill is a residual, in pharmacy it is the deal itself. Understanding what drives it, and how valuations are constructed, is the first step to negotiating from a position of knowledge rather than guesswork.
This post explains what pharmacy goodwill is, how the two main valuation method families work at a conceptual level, what moves the number up or down, and why no reputable adviser will hand you a headline multiple without knowing your specific business. It also covers the corporation tax trap buyers should check before agreeing heads of terms on a company purchase.
The short answer: goodwill is most of the price, and the NHS contract is the reason
In a community pharmacy sale, goodwill is the dominant asset. The dispensing counter, the shopfit and the stock are worth relatively little on their own. What buyers are paying for is the right to operate the NHS community pharmacy contract from that location, and the income stream that flows from it.
That income is contract-driven, not till-driven. The Drug Tariff sets the reimbursement price; the CPCF sets the remuneration fees. A pharmacy with a high, stable dispensing volume and a growing service-income line (such as Pharmacy First) is a reliable income stream with high barriers to entry. That reliability is what buyers price as goodwill.
Item volume is the most visible proxy for that reliability. A higher monthly item count signals a larger, more established patient base and a more deeply embedded local contract. This is why goodwill is often discussed in terms of item volume as well as earnings, and why both method families below anchor to it in different ways.
What goodwill actually is in a pharmacy sale
Legally, goodwill is the excess of the total consideration paid over the fair value of the identifiable net assets. In a pharmacy, those net assets (equipment, stock, any property) are typically a small fraction of the total price. The rest is goodwill.
In practice, pharmacy goodwill bundles together several things that cannot be easily separated:
- The NHS contract itself. Market entry is regulated under the NHS (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013. You cannot simply open a new pharmacy wherever you like; the contract is the scarce asset. A buyer acquires the right to operate from that location and under that contract.
- The dispensing income stream. A well-established dispensing volume signals long-standing patient loyalty and GP referral relationships. That income does not disappear when ownership changes (subject to the transition being well managed).
- Service income lines. Pharmacy First and similar advanced services are a separately accounted, growing revenue line. A pharmacy with a strong and growing service income stream commands a premium over a purely dispensing-focused business.
- Customer base and location. Proximity to GP surgeries, nursing homes, or residential density all feed into future volume expectations.
Because the GPhC registration of premises and the NHS contract travel with the location, not with any individual, goodwill is transferable when the relevant regulatory steps are followed. That transferability is what makes it a bankable asset and a financeable purchase.
Method family 1: a multiple of adjusted EBITDA
The most widely understood valuation method applies a market-derived multiple to the pharmacy's adjusted EBITDA: earnings before interest, tax, depreciation and amortisation, with certain add-backs applied.
What "adjusted" means. Raw EBITDA from the accounts often includes costs that are specific to the current owner and would not transfer to a buyer. Common adjustments include:
- Owner's salary or drawings above (or below) a market-rate pharmacist salary. The valuation should reflect what the business earns after paying a replacement superintendent pharmacist at market rate.
- Personal expenses run through the business that would not continue under new ownership.
- Non-recurring costs or one-off income that inflates or deflates a single year's earnings.
- Rent at a non-arm's length figure (for example where the owner also owns the freehold).
Adjusted EBITDA is therefore a picture of the business's sustainable earning power for a typical owner, stripped of the current owner's specific circumstances. This is the number a buyer is willing to pay a multiple of.
Why we do not state the multiple here. The multiple that a willing buyer and seller agree in the current market is not a fixed number. It reflects current transaction volumes, availability of finance, buyer competition for a specific location, the quality of the income mix, and the condition of the market at the point of sale. Any multiple quoted without a current, named, cited broker source is unreliable at best and misleading at worst. See the dedicated section below on this point.
When this method is most useful. Adjusted-EBITDA approaches are particularly well suited to pharmacies with a meaningful service income line, since service income flows through EBITDA in a way that a pure dispensing-volume metric does not fully capture. They are also common for larger pharmacies where the earnings figure is robust enough to anchor a lender's underwriting.
Method family 2: pence-per-item benchmarks
The second method family values the pharmacy by applying a benchmark price (expressed in pence) to each dispensing item dispensed per year. A pharmacy dispensing a higher volume of items will produce a higher raw goodwill figure under this approach.
What it measures. The pence-per-item approach essentially prices the dispensing throughput directly, treating each item as a unit of contracted income rather than trying to model profitability. It is a volume-anchored method, and it has historically been popular in pharmacy transactions because item volume is transparent, auditable and hard to manipulate.
Its limitation. Two pharmacies dispensing the same number of items can have very different profitability if their service income, margin profile, staffing costs and overheads differ. A high-volume pharmacy with a compressed margin and heavy Category M exposure (where the Drug Tariff clawback mechanism has historically reduced gross margin retrospectively) may look attractive on items but less so on earnings. Buyers and their advisers will cross-check item volume against the earnings picture before accepting a pence-per-item price at face value.
When this method is most useful. It is commonly used as a cross-check alongside adjusted EBITDA, or as the primary lens for smaller, predominantly dispensing pharmacies where the earnings figure may be distorted by owner arrangements.
Again, we do not state a pence-per-item benchmark. The reasons are the same as for the EBITDA multiple: the benchmark moves with market conditions and any figure without a named, current source is unreliable. The section below explains this in full.
Why this post does not quote a multiple or a pence-per-item figure
Pharmacy valuation content online is full of headline multiples and "the market is typically X times" statements. Almost none of them carry a named source, a date, or an explanation of which type of pharmacy they apply to.
A multiple from a publication two years ago, applied to a 30,000-item dispensing pharmacy in a rural location, says almost nothing useful about the price of a 60,000-item urban pharmacy today. Using it as a benchmark could leave a seller significantly undervaluing their business, or lead a buyer to overpay for a business with a compressed margin.
The honest treatment is: the methods exist (adjusted EBITDA multiple; pence-per-item), they are both legitimate and widely used, and the right number requires:
- Current transaction data from a specialist pharmacy broker who has completed comparable deals recently.
- Your specific financials, adjusted correctly.
- An informed view on the drivers covered in the next section.
Your accountant's role in this process is to make sure the adjusted EBITDA figure is constructed correctly, that the add-backs are defensible, and that the tax implications of the agreed price are fully understood before heads of terms are signed. If you are looking for a current market view on multiples, a specialist pharmacy broker with live transaction data is the right source. We can refer you to appropriate specialists through our pharmacy valuation and goodwill service.
What moves your valuation up or down
Within any given method, the output is not mechanical. The following drivers move the adjusted EBITDA figure, the pence-per-item benchmark applied, or both.
| Driver | Direction | Why it matters |
|---|---|---|
| Dispensing item volume | Higher volume, higher value | More items signal a larger, more embedded patient base and more contracted income. The NHS contract is the asset; volume is the evidence of its depth. |
| Service income (including Pharmacy First) | Strong and growing income lifts value | Service income is a separately accounted line with its own fee structure. A pharmacy already earning well from advanced services demonstrates clinical engagement and is positioned for a growing funding line. |
| Margin story and Category M exposure | Opaque or volatile margins discount value | Where a large share of dispensing is Category M drugs, the gross margin is set centrally and retrospectively adjusted. A buyer cannot rely on that margin holding, which increases risk and may reduce the multiple applied to EBITDA. |
| Lease terms | Long, assignable lease adds value; short or conditional lease discounts it | A buyer needs security of tenure to operate the contract and recoup the goodwill price. A lease with fewer than five years unexpired, or onerous alienation clauses, introduces risk that reduces what a buyer will pay. |
| Owner dependency | High dependency discounts value | Where dispensing income or key GP relationships depend on the current owner-pharmacist being present, a buyer faces transition risk. A pharmacy with a stable employed superintendent pharmacist or a self-running team is more transferable. |
| Contract type and history | Clean, unencumbered contracts at full value | Contracts that are under review, subject to conditions or recently relocated carry regulatory risk. Buyers and their solicitors will examine the contract history under the 2013 Regulations before completing. |
These drivers interact. A high-volume pharmacy with strong service income, a transparent margin, a long lease and a well-staffed team will attract buyer interest and negotiate from a strong position. A pharmacy with volume but a short lease, opaque margins and an owner-dependent operation will find buyers pricing in the risk.
The structuring footnote: goodwill and corporation tax relief on a company purchase
If the pharmacy is being sold through a company share deal rather than an asset deal, there is a tax position buyers need to check before agreeing the price.
On a company purchase, corporation tax relief on goodwill is restricted and only available in limited cases at fixed rates. This is different from an asset purchase where the buyer acquires goodwill as a standalone asset; in a share deal, the buyer acquires the company, and the company's goodwill does not attract the same relief profile on the buyer's side.
This restriction is material. A buyer paying a significant sum for goodwill and expecting to obtain corporation tax relief on amortisation over time may find that relief is unavailable or severely limited under a company structure. The after-tax cost of the acquisition is higher than a naive reading of the purchase price suggests.
This is one of the reasons the share-versus-asset purchase decision is the first structuring question in any pharmacy transaction. The share deal inherits the company's history (including any liabilities, tax positions and regulatory history) and carries stamp duty at 0.5% on the share consideration; the asset deal attracts SDLT on any property at non-residential rates up to 5% but gives the buyer a clean asset base and avoids the goodwill relief restriction. The right answer depends on the specific transaction. For a full breakdown of the structuring trade-offs, see our guide on share versus asset purchase for pharmacies.
Getting a proper valuation view
If you are considering a sale or are at an early stage of valuing a pharmacy for purchase, the practical path is:
- Get your adjusted EBITDA figure right. This means working with an accountant who understands pharmacy-specific adjustments: market-rate superintendent salary, Category M margin normalisation, owner expenses, and any non-recurring items. A poorly constructed EBITDA figure is the most common source of valuation disagreements.
- Understand your item volume and its trend. A growing item count over three years tells a different story to a flat or declining one, even if the current volume is the same.
- Commission a specialist pharmacy broker view. Brokers with live pharmacy transaction data can provide a current market range for your business type, location and earnings profile. That range, applied to your adjusted EBITDA or item volume, is the closest thing to a reliable indication of value.
- Review the tax position before heads of terms. Whether you are buying or selling, the tax implications of the structure (BADR availability, goodwill relief position, SDLT versus stamp duty) should be clear before a price is agreed, not after.
Our pharmacy valuation and goodwill service covers the accounting side of this: constructing the adjusted EBITDA, reviewing the financial information presented by a seller, and advising on the tax position for buyer and seller. For buyers working through the affordability arithmetic once a price is in range, the pharmacy purchase affordability calculator can help you model the numbers (it does not itself value the pharmacy and does not assert a multiple; it encodes the purchase arithmetic once you have a price to work with).
If you are at the stage of understanding whether a sale makes sense for your business, or how to present your pharmacy in the best light to maximise the price, start with the selling a pharmacy hub or speak to us directly. For buyers at the research stage, the buying a pharmacy hub covers the end-to-end process.
This post covers England. Scotland, Wales and Northern Ireland have devolved NHS contract arrangements; the valuation principles apply, but the contract specifics differ and will be covered in future posts.